Antiviral drugs in hospitalized patients with COVID-19 – the DisCoVeRy trial

https://www.medrxiv.org/content/10.1101/2021.01.08.20248149v1

NCT04315948- An open-label, randomized, adaptive, controlled trial, multi-center trial was conducted with 583 COVID-19 inpatients requiring oxygen and/or ventilatory support  from France. Adjusted Odds Ratio (aOR) for the WHO 7-point ordinal scale were not in favor of investigational treatments: lopinavir/ritonavir versus control, aOR 0.83, 95%CI, 0.55 to 1.26, P=0.39; lopinavir/ritonavir-IFN-β-1a versus control, aOR 0.69, 95%CI, 0.45 to 1.04, P=0.08; hydroxychloroquine versus control, aOR 0.93, 95%CI, 0.62 to 1.41, P=0.75. No significant effect on SARS-CoV-2 RNA clearance in respiratory tract was evidenced. Lopinavir/ritonavir-containing treatments were significantly associated with more SAE.No improvement of the clinical status at day 15 nor SARS-CoV-2 RNA clearance in respiratory tract specimens by studied drugs. This comforts the recent Solidarity findings.

Tags: